These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 33677950)

  • 1. Pulmonary arterial hypertension: guidelines and unmet clinical needs.
    Giuggioli D; Bruni C; Cacciapaglia F; Dardi F; De Cata A; Del Papa N; Iannone F; Lunardi C; Maglione W; Molinaro F; Palazzini M; Spinella A; Tinazzi E; Matucci Cerinic M
    Reumatismo; 2021 Jan; 72(4):228-246. PubMed ID: 33677950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society Guidelines.
    Distler O; Bonderman D; Coghlan JG; Denton CP; Grünig E; Khanna D; McLaughlin VV; Müller-Ladner U; Pope JE; Vonk MC; Di Scala L; Lemarie JC; Perchenet L; Hachulla É
    Arthritis Rheumatol; 2024 May; 76(5):777-782. PubMed ID: 38146100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for pulmonary arterial hypertension in patients with systemic sclerosis in the era of new pulmonary arterial hypertension definitions.
    Erdogan M; Kilickiran Avci B; Ebren C; Ersoy Y; Ongen Z; Ongen G; Hamuryudan V; Hatemi G
    Clin Exp Rheumatol; 2024 Aug; 42(8):1590-1597. PubMed ID: 38489342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.
    Vilela VS; Dias MM; Salgado ÂA; da Silva BRA; Lopes AJ; Bessa EJC; Bruno LP; da Costa CH; Levy RA; Rufino R
    BMC Pulm Med; 2021 Jul; 21(1):251. PubMed ID: 34325685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognosis and management of reclassified systemic lupus erythematosus associated pulmonary arterial hypertension according to 2022 ESC/ERS guidelines.
    Li Y; Qian J; Dong X; Zhao J; Wang Q; Wang Y; Zeng X; Tian Z; Li M
    Arthritis Res Ther; 2024 May; 26(1):109. PubMed ID: 38802957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension.
    Xanthouli P; Jordan S; Milde N; Marra A; Blank N; Egenlauf B; Gorenflo M; Harutyunova S; Lorenz HM; Nagel C; Theobald V; Lichtblau M; Berlier C; Ulrich S; Grünig E; Benjamin N; Distler O
    Ann Rheum Dis; 2020 Mar; 79(3):370-378. PubMed ID: 31818805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
    Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
    Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How did the updated hemodynamic definitions affect the frequency of pulmonary hypertension in patients with systemic sclerosis?
    Sarı A; Şener YZ; Armağan B; Kılıç L; Kaya EB; Hekimsoy V; Karadağ Ö; Apras Bilgen Ş; Kiraz S; Ertenli I; Tokgozoğlu L; Akdoğan A
    Anatol J Cardiol; 2021 Jan; 25(1):30-35. PubMed ID: 33382047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mild pulmonary hemodynamic alterations in patients with systemic sclerosis: relevance of the new 2022 ESC/ERS definition of pulmonary hypertension and impact on mortality.
    Puigrenier S; Giovannelli J; Lamblin N; De Groote P; Fertin M; Bervar JF; Lamer A; Edmé JL; Balquet MH; Sobanski V; Launay D; Hachulla É; Sanges S
    Respir Res; 2022 Oct; 23(1):284. PubMed ID: 36243869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
    Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R
    Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High sensitivity and negative predictive value of the DETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center.
    Guillén-Del Castillo A; Callejas-Moraga EL; García G; Rodríguez-Palomares JF; Román A; Berastegui C; López-Meseguer M; Domingo E; Fonollosa-Plá V; Simeón-Aznar CP
    Arthritis Res Ther; 2017 Jun; 19(1):135. PubMed ID: 28615037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary arterial hypertension.
    Montani D; Günther S; Dorfmüller P; Perros F; Girerd B; Garcia G; Jaïs X; Savale L; Artaud-Macari E; Price LC; Humbert M; Simonneau G; Sitbon O
    Orphanet J Rare Dis; 2013 Jul; 8():97. PubMed ID: 23829793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension.
    Di Benedetto P; Guggino G; Manzi G; Ruscitti P; Berardicurti O; Panzera N; Grazia N; Badagliacca R; Riccieri V; Vizza CD; Radchenko G; Liakouli V; Ciccia F; Cipriani P; Giacomelli R
    Arthritis Res Ther; 2020 Jun; 22(1):127. PubMed ID: 32487240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study.
    Karia N; Howard L; Johnson M; Kiely DG; Lordan J; McCabe C; Pepke-Zaba J; Ong R; Preiss M; Knight D; Muthurangu V; Coghlan JG
    Eur Heart J; 2023 Nov; 44(44):4678-4691. PubMed ID: 37619574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definitions and diagnosis of pulmonary hypertension.
    Hoeper MM; Bogaard HJ; Condliffe R; Frantz R; Khanna D; Kurzyna M; Langleben D; Manes A; Satoh T; Torres F; Wilkins MR; Badesch DB
    J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D42-50. PubMed ID: 24355641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se.
    Lindholm A; Hesselstrand R; Rådegran G; Arheden H; Ostenfeld E
    Clin Physiol Funct Imaging; 2019 May; 39(3):215-225. PubMed ID: 30597705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.
    Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG
    Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Systemic sclerosis associated pulmonary arterial hypertension: the pitfalls].
    Hachulla E; Launay D; Le Pavec J; Mouthon L; Guillevin L; de Groote P
    Presse Med; 2011 Apr; 40 Suppl 1():1S46-53. PubMed ID: 21536180
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.